Population health doesn’t have to mean boiling the ocean

Todd Van Meter, CEO of Accuity, says that when partnering with clients, initial clinical denial rates are nearly cut in half and following an appeals process using an AI-driven platform, the final denial rates end up at 1% to 1.5%.

The U.S. Food and Drug Administration's validation requirements process for drug development is a good model for healthcare artificial intelligence governance, explains Michael Abrams, managing partner at Numerof & Associates.

Surgeon and futurist Dr. Shafi Ahmed talks about how AI is shaping healthcare's future, including its use in digital surgery, drug development, wearables, genomic medicine and clinical decision support.